ATE183233T1 - Verwendung des keratinozyten wachstumsfaktors (kgf) für die herstellung von arzneimitteln - Google Patents

Verwendung des keratinozyten wachstumsfaktors (kgf) für die herstellung von arzneimitteln

Info

Publication number
ATE183233T1
ATE183233T1 AT94104804T AT94104804T ATE183233T1 AT E183233 T1 ATE183233 T1 AT E183233T1 AT 94104804 T AT94104804 T AT 94104804T AT 94104804 T AT94104804 T AT 94104804T AT E183233 T1 ATE183233 T1 AT E183233T1
Authority
AT
Austria
Prior art keywords
kgf
growth factor
medicinal products
keratinocyte growth
producing medicinal
Prior art date
Application number
AT94104804T
Other languages
English (en)
Inventor
Glenn F Pierce
Regina M Housley
Charles F Morris
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE183233(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE183233T1 publication Critical patent/ATE183233T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
AT94104804T 1993-03-26 1994-03-25 Verwendung des keratinozyten wachstumsfaktors (kgf) für die herstellung von arzneimitteln ATE183233T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4074293A 1993-03-26 1993-03-26

Publications (1)

Publication Number Publication Date
ATE183233T1 true ATE183233T1 (de) 1999-08-15

Family

ID=21912689

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94104804T ATE183233T1 (de) 1993-03-26 1994-03-25 Verwendung des keratinozyten wachstumsfaktors (kgf) für die herstellung von arzneimitteln

Country Status (23)

Country Link
EP (1) EP0619370B1 (de)
JP (1) JP3578761B2 (de)
KR (1) KR100390340B1 (de)
CN (1) CN1064710C (de)
AT (1) ATE183233T1 (de)
AU (1) AU707340B2 (de)
CA (1) CA2159109C (de)
CZ (1) CZ285996B6 (de)
DE (1) DE69419958T2 (de)
DK (1) DK0619370T3 (de)
ES (1) ES2136673T3 (de)
FI (1) FI954541L (de)
GR (1) GR3031509T3 (de)
HU (1) HU220641B1 (de)
IL (4) IL137581A (de)
NO (1) NO953781L (de)
NZ (1) NZ263967A (de)
RU (1) RU2146148C1 (de)
SG (1) SG49841A1 (de)
SI (1) SI0619370T1 (de)
SK (1) SK281674B6 (de)
UA (1) UA46706C2 (de)
WO (1) WO1994023032A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
WO1996011949A2 (en) * 1994-10-13 1996-04-25 Amgen Inc. Analogs of keratinocyte growth factor
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
WO1996025422A1 (en) * 1995-02-14 1996-08-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
PT871730E (pt) * 1995-10-11 2004-11-30 Chiron Corp Combinacao de pdgf, kgf, igf e igfbp para cicatrizacao de ferimentos
GB9619660D0 (en) * 1996-09-20 1996-11-06 Scient Hospital Suppl Int Ltd Prevention of gastrointestinal damage
SI0941110T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Uses of keratinocyte growth factor-2
WO1998016243A1 (en) * 1996-10-15 1998-04-23 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US6228839B1 (en) * 1997-12-19 2001-05-08 Emory University Use of keratinocyte growth factor to improve oxidative status
WO1999032135A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6599879B1 (en) 1998-02-13 2003-07-29 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
WO2001070255A2 (en) 2000-03-20 2001-09-27 Pfizer Products, Inc. Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
CN1491231A (zh) * 2001-02-06 2004-04-21 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰角质形成细胞生长因子(kgf)
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
RU2243784C2 (ru) * 2003-02-25 2005-01-10 Козлов Владимир Александрович Способ лечения больных хроническим гепатитом
EP1789138A2 (de) * 2004-09-13 2007-05-30 University Of Southampton Wachstumsfaktorbehandlung bei asthma
RU2391990C1 (ru) * 2008-11-25 2010-06-20 Александр Сергеевич Ботин Композиция для стимулирования роста и регенерации клеток, (варианты), а также способ ее получения (варианты)
CN101822821B (zh) * 2010-04-27 2013-01-23 复旦大学附属中山医院 角质细胞生长因子-2在制备防治肺损伤的药物中的应用
CN104707164B (zh) * 2015-03-31 2017-01-18 中国人民解放军军事医学科学院基础医学研究所 一种复合壳聚糖水凝胶敷料及其制备方法和应用
CN106226511B (zh) * 2016-07-28 2018-04-06 苏州金盟生物技术有限公司 一种重组人角质细胞生长因子生物学活性检测方法
CN107753932A (zh) * 2016-08-22 2018-03-06 中国辐射防护研究院 Kgf在制备治疗或预防放射性肠炎药物中的用途
JP7135106B2 (ja) 2018-11-27 2022-09-12 株式会社海月研究所 頭皮頭髪用組成物
KR20210114646A (ko) * 2020-03-11 2021-09-24 (주)메디코스바이오텍 성장인자를 함유하는 탈모 치료 또는 모발 성장 촉진용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2250213C2 (ru) * 1989-01-31 2005-04-20 Джеффри С. РУБИН Выделенный белок фактора роста кератиноцита (kgf), рекомбинантная молекула днк, вектор, способ конструирования клетки-хозяина, способ получения белка, фармацевтическая композиция
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
JPH05506673A (ja) * 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用

Also Published As

Publication number Publication date
CZ285996B6 (cs) 1999-12-15
HU220641B1 (hu) 2002-03-28
KR100390340B1 (ko) 2003-09-26
NZ263967A (en) 2005-02-25
UA46706C2 (uk) 2002-06-17
CA2159109A1 (en) 1994-10-13
CN1064710C (zh) 2001-04-18
KR960701204A (ko) 1996-02-24
FI954541A7 (fi) 1995-11-23
SK281674B6 (sk) 2001-06-11
HUT72711A (en) 1996-05-28
CZ248295A3 (en) 1996-12-11
JP2002526026A (ja) 2002-08-13
AU6524394A (en) 1994-10-24
ES2136673T3 (es) 1999-12-01
JP3578761B2 (ja) 2004-10-20
DK0619370T3 (da) 2000-02-28
DE69419958T2 (de) 2000-04-20
AU707340B2 (en) 1999-07-08
RU2146148C1 (ru) 2000-03-10
GR3031509T3 (en) 2000-01-31
DE69419958D1 (de) 1999-09-16
HU9502800D0 (en) 1995-12-28
CA2159109C (en) 2004-11-16
IL109122A0 (en) 1994-06-24
IL109122A (en) 2004-07-25
EP0619370B1 (de) 1999-08-11
FI954541A0 (fi) 1995-09-25
WO1994023032A1 (en) 1994-10-13
FI954541L (fi) 1995-11-23
IL137581A0 (en) 2001-07-24
NO953781L (no) 1995-11-27
IL161568A0 (en) 2004-09-27
IL137581A (en) 2009-09-01
SI0619370T1 (en) 1999-10-31
EP0619370A1 (de) 1994-10-12
NO953781D0 (no) 1995-09-25
SG49841A1 (en) 1998-06-15
SK118595A3 (en) 1996-11-06
CN1217022A (zh) 1999-05-19

Similar Documents

Publication Publication Date Title
ATE183233T1 (de) Verwendung des keratinozyten wachstumsfaktors (kgf) für die herstellung von arzneimitteln
Ferguson et al. Scar formation: the spectral nature of fetal and adult wound repair
Sonis Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
ATE308545T1 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE502004010144D1 (de) Verwendung eines Extrakts aus Bauhinia zur Herstellung kosmetischer und pharmazeutischer Zubereitungen
FR2644066B1 (fr) Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
DE69328527D1 (de) Carboxypeptidase-ähnliches Protein aus Knochen und Verfahren zur dessen Herstellung
DE69738336D1 (de) Verwendung von keratinocyte growth factor-2
ATE428438T1 (de) Tcf-ii enthaltende medizinische zusammensetzung
AU1200488A (en) Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci
RU2090155C1 (ru) Способ пластики хрящевого дефекта спинки носа
RU2210352C1 (ru) Композиция для лечения воспалительных заболеваний пародонта на основе клеточных культур
Bang et al. Immunohistochemical study of TGF-β on the healing process in the rat femur bone defect
ATE357520T1 (de) Biologisches material zur behandlung eines säugetieres durch transfer einesfür einen antikörper kodierendes gen und eine pharmazeutische zusammensetzungdie diese enthält
Martin-Granizo et al. The maxillofacial scope for using the CO2 laser in intraoral lesions
Blinder et al. Dental extractions in patients treated with oral anticoagulant: Comparison of local hemostatic modalities
Filippi Ozone Research Repository
UA28342A (uk) Спосіб одержання біологічно активної речовини для лікування серцевих захворювань
TH41485A (th) วิธีสำหรับรักษาภาวะการแข็งตัวของเลือดเกินหรือภาวะการพร่องโปรตีนชีที่ได้รับภายหลัง

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner